- Home
- DCTH vs ENGN Comparison
DCTH vs ENGN Comparison
Compare DCTH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- ENGN
- Stock Information
- Founded
- DCTH 1988
- ENGN 1999
- Country
- DCTH United States
- ENGN Canada
- Employees
- DCTH 76
- ENGN N/A
- Industry
- DCTH Medical/Dental Instruments
- ENGN
- Sector
- DCTH Health Care
- ENGN
- Exchange
- DCTH Nasdaq
- ENGN Nasdaq
- Market Cap
- DCTH 387.2M
- ENGN 293.1M
- IPO Year
- DCTH N/A
- ENGN N/A
- Fundamental
- Price
- DCTH $12.11
- ENGN $6.08
- Analyst Decision
- DCTH Strong Buy
- ENGN Strong Buy
- Analyst Count
- DCTH 4
- ENGN 8
- Target Price
- DCTH $21.50
- ENGN $30.38
- AVG Volume (30 Days)
- DCTH 389.9K
- ENGN 188.1K
- Earning Date
- DCTH 11-08-2024
- ENGN 01-27-2025
- Dividend Yield
- DCTH N/A
- ENGN N/A
- EPS Growth
- DCTH N/A
- ENGN N/A
- EPS
- DCTH N/A
- ENGN N/A
- Revenue
- DCTH $22,644,000.00
- ENGN N/A
- Revenue This Year
- DCTH $1,605.13
- ENGN N/A
- Revenue Next Year
- DCTH $111.67
- ENGN N/A
- P/E Ratio
- DCTH N/A
- ENGN N/A
- Revenue Growth
- DCTH 945.91
- ENGN N/A
- 52 Week Low
- DCTH $3.10
- ENGN $4.42
- 52 Week High
- DCTH $12.88
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- DCTH 60.66
- ENGN 26.04
- Support Level
- DCTH $11.48
- ENGN $8.00
- Resistance Level
- DCTH $12.38
- ENGN $7.97
- Average True Range (ATR)
- DCTH 0.70
- ENGN 0.72
- MACD
- DCTH 0.06
- ENGN -0.24
- Stochastic Oscillator
- DCTH 77.56
- ENGN 2.22
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.